0001209191-22-033544.txt : 20220602
0001209191-22-033544.hdr.sgml : 20220602
20220602163651
ACCESSION NUMBER: 0001209191-22-033544
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220531
FILED AS OF DATE: 20220602
DATE AS OF CHANGE: 20220602
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zeronda Tyler
CENTRAL INDEX KEY: 0001867033
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38356
FILM NUMBER: 22991365
MAIL ADDRESS:
STREET 1: C/O VYNE THERAPEUTICS
STREET 2: 520 U.S. HIGHWAY 22, SUITE 204
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VYNE Therapeutics Inc.
CENTRAL INDEX KEY: 0001566044
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453757789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 520 U.S. HIGHWAY 22, SUITE 204
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
BUSINESS PHONE: 800-775-7936
MAIL ADDRESS:
STREET 1: 520 U.S. HIGHWAY 22, SUITE 204
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics Inc.
DATE OF NAME CHANGE: 20180201
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics, Inc.
DATE OF NAME CHANGE: 20170728
FORMER COMPANY:
FORMER CONFORMED NAME: Tigercat Pharma, Inc.
DATE OF NAME CHANGE: 20130104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-05-31
0
0001566044
VYNE Therapeutics Inc.
VYNE
0001867033
Zeronda Tyler
C/O VYNE THERAPEUTICS, INC.
520 U.S. HIGHWAY 22, SUITE 204
BRIDGEWATER
NJ
08807
0
1
0
0
CFO
Common Stock
2022-05-31
5
A
0
E
12510
0.3463
A
174066
D
These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2021 and ending on May 31, 2022 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 31, 2022 (the last trading day of the offering period).
/s/ Mutya Harsch, attorney-in-fact for Tyler Zeronda
2022-06-02